BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Monday, January 6, 2025
See today's BioWorld
Home
» Zai Lab nabs $761M via secondary listing in Hong Kong
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Zai Lab nabs $761M via secondary listing in Hong Kong
Sep. 28, 2020
By
David Ho
No Comments
HONG KONG – U.S. listed Chinese biotech company Zai Lab Ltd. has raised $761 million in its secondary listing on the Hong Kong Stock Exchange.
BioWorld
Financings
Cancer
IPO
Asia-Pacific
